V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009007 | 220003642 | null | 0 | Palliative (P) | 2017-06-27 | 2017-06-27 | BOSUTINIB | 2 | N | 220035690 | DOCETAXEL |
| 220009008 | 220003643 | 1.58 | 62.6 | Adjuvant (A) | 2013-08-21 | 2013-09-26 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 220035693 | UKALL2014 |
| 220009009 | 220003644 | null | 81.3 | Palliative (P) | 2017-08-13 | 2017-08-14 | Bortezomib +/- Dexamethasone | N | N | 220035694 | DACARBAZINE |
| 220009010 | 220011979 | 1.5 | null | Palliative (P) | 2014-09-25 | 2014-10-08 | PACLITAXEL | N | N | 220035695 | IRINOTECAN + MDG |
| 220009011 | 220011979 | 1.39 | 105 | Disease modification (D) | 2016-01-04 | 2016-01-04 | MACE | 02 | N | 220035695 | BOSUTINIB |
| 220009012 | 220003645 | 1.8 | 129 | Curative (C) | 2014-02-02 | 2014-02-02 | LANREOTIDE | 02 | N | 220035700 | METHOTREXATE INTRATHECAL |
| 220009013 | 220003645 | 1.75 | 70 | Palliative (P) | 2014-10-22 | 2014-10-22 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA | 2 | null | 220035700 | CISPLATIN + ETOPOSIDE |
| 220009014 | 220003645 | 1.76 | 61 | Palliative (P) | 2015-12-05 | 2015-12-10 | DABRAFENIB + TRAMETINIB | 2 | N | 220035700 | DACARBAZINE |
| 220009015 | 220003645 | 0 | 31.1 | Curative (C) | 2017-05-08 | 2017-05-16 | Busulfan + Cyclophos Conditioning | 2 | N | 220035700 | BLINATUMOMAB |
| 220009016 | 220003646 | 1.55 | 71.5 | Palliative (P) | 2017-03-07 | 2017-08-04 | Fludarabine + Melphalan RIC Allo | N | N | 220035713 | CTD |
| 220009017 | 220003647 | null | 66 | Not known (9) | 2013-06-22 | 2013-06-29 | DABRAFENIB + TRAMETINIB | 02 | N | 220035715 | CAPECITABINE + CARBOPLATIN |
| 220009018 | 220003647 | 0 | 87 | Curative (C) | 2014-03-27 | 2014-03-27 | CVP R | N | N | 220035715 | ALEMTUZUMAB |
| 220009019 | 220003647 | null | null | Curative (C) | 2015-02-19 | 2015-03-10 | IPILIMUMAB + NIVOLUMAB | N | N | 220035715 | CYCLOPHOSPHAMIDE |
| 220009020 | 220003648 | 1.68 | 67.3 | Palliative (P) | 2017-08-07 | 2017-08-08 | CHOP R - 21 days | N | N | 220035723 | DABRAFENIB |
| 220009021 | 220003649 | 1.64 | null | null | 2018-02-18 | 2018-02-18 | RUXOLITINIB | null | null | 220035728 | BUSULPHAN |
| 220009022 | 220003649 | null | null | Curative (C) | 2013-04-12 | 2013-04-15 | Docetaxel | Y | N | 220035728 | UKALL2014 |
| 220009023 | 220016469 | 0 | 63.15 | Palliative (P) | 2013-01-24 | 2013-01-24 | FEC 100 | 2 | null | 220035731 | LANREOTIDE |
| 220009024 | 220003650 | 1.6 | 59.5 | Palliative (P) | 2016-08-14 | 2016-08-14 | Carboplatin + Pemetrexed | 2 | N | 220035734 | DACARBAZINE |
| 220009025 | 220003651 | 1.58 | 57.9 | Neo-adjuvant (N) | 2015-04-24 | 2015-05-20 | Docetaxel + Trastuzumab (Load) | N | N | 220035735 | CARBOPLATIN + RT |
| 220009026 | 220003651 | 1.67 | 112 | Palliative (P) | 2016-09-18 | 2017-04-10 | Irinotecan + Modified De Gramont | N | N | 220035735 | CAPECITABINE |
| 220009027 | 220003651 | 0 | 61.1 | Palliative (P) | 2015-01-30 | 2015-01-30 | Cisplatin + Pemetrexed | 02 | N | 220035735 | IRINOTECAN + MDG |
| 220009028 | 220019040 | 1.68 | 57.9 | Palliative (P) | 2017-02-25 | 2017-02-25 | TRASTUZUMAB EMTANSINE | 02 | N | 220035742 | VEMURAFENIB |
| 220009031 | 220011984 | 1.84 | 72 | null | 2016-11-18 | 2016-11-21 | CARBOPLATIN + RT | N | null | 220035759 | FLUDARABINE |
| 220009032 | 220011984 | 1.76 | 75.7 | Palliative (P) | 2015-03-13 | 2015-03-20 | Ipilimumab | 02 | N | 220035759 | CISPLATIN + PEMETREXED |
| 220009033 | 220019041 | 1.8 | 117 | Palliative (P) | 2013-05-26 | 2013-05-31 | RUXOLITINIB | 2 | null | 220035762 | ENZALUTAMIDE |
| 220009034 | 220003654 | 1.63 | null | Palliative (P) | null | 2015-02-28 | Ipilimumab | null | null | 220035764 | RUXOLITINIB |
| 220009035 | 220003655 | 0 | 77.4 | Palliative (P) | 2015-05-04 | 2015-05-04 | Bortezomib + Cyclophos + Dex | 01 | N | 220035765 | SORAFENIB |
| 220009036 | 220003656 | 1.66 | 69.7 | null | 2016-08-31 | 2016-09-07 | ETOPOSIDE | N | null | 220035767 | ROMAZA TRIAL |
| 220009037 | 220003656 | 1.84 | null | Palliative (P) | 2017-01-20 | 2017-01-20 | CYTARABINE + MITOXANTRONE | 2 | N | 220035767 | IPILIMUMAB + NIVOLUMAB |
| 220009038 | 220003656 | 1.67 | 56.25 | Curative (C) | null | 2013-02-14 | Cisplatin + Etoposide (5 day) | null | N | 220035767 | CARBOPLATIN + RT |
| 220009039 | 220003656 | 1.74 | 69.5 | Curative (C) | 2014-08-26 | 2014-08-26 | IDARUBICIN | 02 | N | 220035767 | CISPLATIN |
| 220009040 | 220003656 | 1.61 | 65.3 | Adjuvant (A) | null | 2014-09-09 | Capecitabine | N | N | 220035767 | FEC |
| 220009041 | 220021331 | 1.66 | -1 | Palliative (P) | null | 2017-12-20 | UKALL 14 TRIAL | Y | N | 220035775 | CISPLATIN + FLUOROURACIL |
| 220009042 | 220021331 | null | null | Curative (C) | 2014-11-12 | 2014-11-13 | LENALIDOMIDE | N | N | 220035775 | CYCLOPHOSPHAMIDE |
| 220009043 | 220003657 | 1.55 | 84.6 | Palliative (P) | 2014-09-17 | 2014-10-17 | IDARUBICIN + MITOXANTRONE + Tretinoin | N | N | 220035777 | OCTREOTIDE |
| 220009044 | 220003657 | 1.49 | 59.7 | Palliative (P) | 2012-10-16 | 2014-04-27 | RUXOLITINIB | N | N | 220035777 | DACARBAZINE |
| 220009045 | 220003657 | 1.6 | 91 | Palliative (P) | 2013-08-12 | 2015-06-10 | OCTREOTIDE | N | N | 220035777 | CETUXIMAB + IRINOTECAN + MDG |
| 220009046 | 220003657 | 1.73 | 59.7 | Palliative (P) | 2017-05-24 | 2017-05-24 | IPILIMUMAB + NIVOLUMAB | 2 | N | 220035777 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 220009047 | 220003657 | 1.78 | 88 | Adjuvant (A) | 2013-07-03 | 2013-07-03 | IDARUBICIN | N | N | 220035777 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009049 | 220003659 | 1.69 | 75 | Palliative (P) | 2015-11-25 | 2015-12-09 | IDARUBICIN + MITOXANTRONE + Tretinoin | 02 | N | 220035790 | TEMOZOLOMIDE + RT |
| 220009050 | 220011987 | 1.72 | 69.699 | Curative (C) | 2013-07-31 | 2013-07-31 | FLUDARABINE | N | N | 220035791 | FBC |
| 220009051 | 220011987 | 1.8 | 74 | Disease modification (D) | 2014-09-13 | 2014-09-13 | DABRAFENIB + TRAMETINIB | 01 | N | 220035791 | CVP R |
| 220009052 | 220011987 | null | 92.3 | null | 2015-02-03 | 2015-02-03 | ECarboX | null | null | 220035791 | CISPLATIN + FLUOROURACIL |
| 220009053 | 220020512 | 1.68 | 71.1 | Not known (9) | null | 2015-09-07 | UKALL14- Ph 1 Induction | N | N | 220035795 | FEC |
| 220009054 | 220021332 | 0 | 74.1 | Disease modification (D) | 2018-05-30 | 2018-05-30 | LIPOSOMAL DAUNORUBICIN | 02 | N | 220035796 | IBRUTINIB |
| 220009055 | 220021332 | 1.81 | 74 | Palliative (P) | 2014-04-27 | 2014-04-27 | GEFITINIB | N | N | 220035796 | GEMCITABINE + NAB-PACLITAXEL |
| 220009056 | 220003660 | 1.83 | 74 | Palliative (P) | 2014-09-10 | 2014-09-10 | Cyclophosphamide TBI Allograft | 02 | Y | 220035799 | CETUXIMAB + IRINOTECAN + MDG |
| 220009057 | 220003661 | null | null | null | 2015-09-12 | 2015-09-13 | Irinotecan + Modified De Gramont | null | null | 220035800 | CYTARABINE INTRATHECAL |
| 220009058 | 220003661 | 1.7 | 88 | Palliative (P) | 2013-11-21 | 2013-12-05 | LENALIDOMIDE | N | N | 220035800 | CISPLATIN + ETOPOSIDE |
| 220009059 | 220003661 | 1.81 | 88.9 | Neo-adjuvant (N) | null | 2017-12-20 | THALIDOMIDE | N | N | 220035800 | BLEOMYCIN + CISPLATIN + VINCRISTINE |